Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
Kinetics of Drug Elimination01:17

Kinetics of Drug Elimination

Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Biological Methods for Microbial Control01:28

Biological Methods for Microbial Control

Biological agents offer an effective means of controlling microbial growth by leveraging natural processes like predation, competition, and the secretion of antimicrobial substances.Predatory bacteria such as Bdellovibrio species target and kill pathogens like Salmonella and E. coli. They are widely used in poultry farms to control infections. Myxococcus species help combat plant-pathogenic fungi. These naturally occurring predators serve as eco-friendly alternatives to chemical pesticides and...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).

Expert review of vaccines·2026
Same author

Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Is the interplay between maternal Tdap and pneumococcal conjugate vaccines relevant to infant pneumococcal carriage?

The Journal of infectious diseases·2026
Same author

What is driving the resurgence and persistence of vaccine-targeted pneumococcal serotypes?-Serotype 19F as the paradigm.

PLoS pathogens·2026
Same author

Differential Impact of Pneumococcal Conjugate Vaccines on Hospitalized <i>Versus</i> Outpatient Community-Acquired Alveolar Pneumonia in Children Younger Than 5 Years Suggests Differences in Pathogenesis.

Open forum infectious diseases·2025
Same author

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children.

Expert review of anti-infective therapy·2025

Related Experiment Video

Updated: Jun 14, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.

Ron Dagan1

  • 1The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer-Sheva, Israel. rdagan@bgumail.bgu.ca.il

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|July 4, 2003
PubMed
Summary

New extra-strength amoxicillin-clavulanate shows higher success rates against resistant bacteria in otitis media. Higher doses overcome penicillin resistance in Streptococcus pneumoniae, improving treatment outcomes.

More Related Videos

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli
12:29

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Published on: March 24, 2023

Related Experiment Videos

Last Updated: Jun 14, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli
12:29

Population and Single-Cell Analysis of Antibiotic Persistence in Escherichia coli

Published on: March 24, 2023

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antimicrobial resistance significantly impacts treatment efficacy in otitis media.
  • Penicillin resistance in Streptococcus pneumoniae can be overcome by optimizing dosing strategies.
  • Pharmacokinetic/pharmacodynamic (PK/PD) parameters are crucial for predicting antimicrobial success against resistant strains.

Purpose of the Study:

  • To evaluate the efficacy of a new extra-strength amoxicillin-clavulanate formulation in treating acute otitis media.
  • To assess the PK/PD profile of the extra-strength formulation against resistant bacterial pathogens.
  • To compare the effectiveness of the new formulation with conventional dosing regimens.

Main Methods:

  • Open-label, non-comparative study in children with acute otitis media.
  • Administration of extra-strength amoxicillin-clavulanate (90/6.4 mg/kg/day divided q12h).
  • Evaluation of bacteriologic success rates against major respiratory pathogens, including penicillin-resistant S. pneumoniae.

Main Results:

  • High bacteriologic success rates observed with the extra-strength formulation.
  • Effective against penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae.
  • PK/PD profiles predict enhanced efficacy against elevated amoxicillin MICs.

Conclusions:

  • The extra-strength amoxicillin-clavulanate formulation demonstrates high efficacy in treating acute otitis media, including cases with resistant pathogens.
  • Optimizing antimicrobial dosing based on PK/PD parameters is essential for overcoming resistance.
  • Future antimicrobial development should prioritize meeting PK/PD targets for bacterial eradication of both susceptible and resistant strains.